Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients

(University of Texas M. D. Anderson Cancer Center) Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news